Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of
linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or
previously treated type 2 diabetic patients with moderate to severe renal impairment and
insufficient glycaemic control. In addition safety in this patient population with longer
term (40 week) treatment in comparison to sulfonylurea drug (glimepiride).